These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 8138660)

  • 41. Tartrate-resistant acid phosphatase 5b activity is a useful bone marker for monitoring bone metastases in breast cancer patients after treatment.
    Chung YC; Ku CH; Chao TY; Yu JC; Chen MM; Lee SH
    Cancer Epidemiol Biomarkers Prev; 2006 Mar; 15(3):424-8. PubMed ID: 16537696
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of bone scanning and CA 15-3 serum concentration in the follow-up of breast cancer.
    Montravers F; Younsi N; Rousseau C; Philippe C; Seddiki M; Uzan S; Izrael V; Talbot JN
    Anticancer Res; 1997; 17(3B):1683-6. PubMed ID: 9179218
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Serum calcium, alkaline phosphotase and hemoglobin as risk factors for bone metastases in bladder cancer.
    Huang P; Lan M; Peng AF; Yu QF; Chen WZ; Liu ZL; Liu JM; Huang SH
    PLoS One; 2017; 12(9):e0183835. PubMed ID: 28902911
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The value of the tumor marker CA 15-3 in diagnosing and monitoring breast cancer. A comparative study with carcinoembryonic antigen.
    Safi F; Kohler I; Röttinger E; Beger H
    Cancer; 1991 Aug; 68(3):574-82. PubMed ID: 2065278
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases.
    Berruti A; Dogliotti L; Gorzegno G; Torta M; Tampellini M; Tucci M; Cerutti S; Frezet MM; Stivanello M; Sacchetto G; Angeli A
    Clin Chem; 1999 Aug; 45(8 Pt 1):1240-7. PubMed ID: 10430790
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prognostic factors and survival according to tumour subtype in women presenting with breast cancer bone metastases at initial diagnosis: a SEER-based study.
    Li X; Zhang X; Liu J; Shen Y
    BMC Cancer; 2020 Nov; 20(1):1102. PubMed ID: 33187507
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Objective measurement of therapeutic response in breast cancer using tumour markers.
    Robertson JF; Pearson D; Price MR; Selby C; Blamey RW; Howell A
    Br J Cancer; 1991 Oct; 64(4):757-63. PubMed ID: 1911226
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Relationship of osteolytic biochemical indicators of bone metabolism with the therapeutic effect in breast cancer patients with bone metastases].
    Li SF; Wang XR; Wang C; Chen Y; Ren L; Cui L; Tong ZS
    Zhonghua Zhong Liu Za Zhi; 2009 Dec; 31(12):911-5. PubMed ID: 20193330
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer.
    Wang W; Xu X; Tian B; Wang Y; Du L; Sun T; Shi Y; Zhao X; Jing J
    Clin Chim Acta; 2017 Jul; 470():51-55. PubMed ID: 28457854
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evaluation of serum CA15-3 determination with CEA and TPA in the post-operative follow-up of breast cancer patients.
    Nicolini A; Colombini C; Luciani L; Carpi A; Giuliani L
    Br J Cancer; 1991 Jul; 64(1):154-8. PubMed ID: 1854615
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Use of serial FDG PET to measure the response of bone-dominant breast cancer to therapy.
    Stafford SE; Gralow JR; Schubert EK; Rinn KJ; Dunnwald LK; Livingston RB; Mankoff DA
    Acad Radiol; 2002 Aug; 9(8):913-21. PubMed ID: 12186440
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Urinary carboxyterminal telopeptide of collagen I as a potential marker of bone metastases chemotherapy monitoring in breast cancer.
    Houzé P; Bellik B; Extra JM; Bouro F; Bousquet B
    Clin Chim Acta; 1999 Mar; 281(1-2):77-88. PubMed ID: 10217629
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Circulating CA 15.3 levels in breast cancer. Our present experience.
    Colomer R; Ruibal A; Navarro M; Encabo G; Sole LA; Salvador L
    Int J Biol Markers; 1986; 1(2):89-92. PubMed ID: 3480915
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Biochemical markers for assessment of bone metastases in patients with breast cancer.
    Hou MF; Tsai LY; Tsai SM; Huang CJ; Huang YS; Hsieh JS; Chan HM; Wang JY; Chuang CH; Chen FM; Huang TJ
    Kaohsiung J Med Sci; 1999 Aug; 15(8):452-60. PubMed ID: 10518361
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Multivariate analysis of serum tumor markers for diagnosis of skeletal metastases.
    Shinozaki T; Chigira M; Kato K
    Cancer; 1992 Jan; 69(1):108-12. PubMed ID: 1370133
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Serological markers for metastatic breast cancer.
    Ng JS; Sturgeon CM; Seth J; Paterson GM; Roulston JE; Leonard RC
    Dis Markers; 1993 Dec; 11(5-6):217-23. PubMed ID: 8082311
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Application of Bone Turnover Markers PICP and β-CTx in the Diagnosis and Treatment of Breast Cancer with Bone Metastases.
    Song B; Li X; Zhou Q; Yang X; Jiang Y; Wang A
    Clin Lab; 2018 Jan; 64(1):11-16. PubMed ID: 29479886
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [CA 15-3 associated with CEA and TPA in the follow-up of breast carcinoma].
    Maffei S; Rudoni M; Antonini G; Sacchetti G; Krengli M
    Minerva Med; 1990 Nov; 81(11):759-63. PubMed ID: 2255409
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pyridinium crosslinks as markers of bone resorption in patients with breast cancer.
    Paterson CR; Robins SP; Horobin JM; Preece PE; Cuschieri A
    Br J Cancer; 1991 Nov; 64(5):884-6. PubMed ID: 1931610
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Usefulness of pyridinium crosslinks and CA 15-3 as markers in metastatic bone breast carcinoma.
    Massidda B; Ionta MT; Foddi MR; Mascia L; Bruder F; Aloi MB; Meleddu C; Giannoni MN
    Anticancer Res; 1996; 16(4B):2221-3. PubMed ID: 8694547
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.